Apex Biotechnology Corp - Asset Resilience Ratio
Apex Biotechnology Corp (1733) has an Asset Resilience Ratio of 3.32% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2002–2024)
This chart shows how Apex Biotechnology Corp's Asset Resilience Ratio has changed over time. Check Apex Biotechnology Corp PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Apex Biotechnology Corp's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Apex Biotechnology Corp market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$76.63 Million | 3.32% |
| Total Liquid Assets | NT$76.63 Million | 3.32% |
Asset Resilience Insights
- Limited Liquidity: Apex Biotechnology Corp maintains only 3.32% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Apex Biotechnology Corp Industry Peers by Asset Resilience Ratio
Compare Apex Biotechnology Corp's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
ALTEOGEN Inc
KQ:196170 |
Biotechnology | 55.57% |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE |
Biotechnology | 47.01% |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX |
Biotechnology | 34.94% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Galapagos N.V.
AS:GLPG |
Biotechnology | 86.45% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
Annual Asset Resilience Ratio for Apex Biotechnology Corp (2002–2024)
The table below shows the annual Asset Resilience Ratio data for Apex Biotechnology Corp.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 2.73% | NT$66.10 Million ≈ $2.08 Million |
NT$2.42 Billion ≈ $76.24 Million |
+0.04pp |
| 2023-12-31 | 2.69% | NT$61.87 Million ≈ $1.95 Million |
NT$2.30 Billion ≈ $72.37 Million |
+0.08pp |
| 2022-12-31 | 2.62% | NT$65.83 Million ≈ $2.07 Million |
NT$2.51 Billion ≈ $79.23 Million |
-0.22pp |
| 2021-12-31 | 2.84% | NT$75.92 Million ≈ $2.39 Million |
NT$2.67 Billion ≈ $84.13 Million |
+1.48pp |
| 2020-12-31 | 1.36% | NT$36.01 Million ≈ $1.13 Million |
NT$2.65 Billion ≈ $83.53 Million |
-3.95pp |
| 2019-12-31 | 5.31% | NT$149.31 Million ≈ $4.70 Million |
NT$2.81 Billion ≈ $88.66 Million |
+2.01pp |
| 2018-12-31 | 3.29% | NT$83.78 Million ≈ $2.64 Million |
NT$2.55 Billion ≈ $80.20 Million |
+0.52pp |
| 2017-12-31 | 2.77% | NT$74.84 Million ≈ $2.36 Million |
NT$2.70 Billion ≈ $85.06 Million |
+1.48pp |
| 2016-12-31 | 1.29% | NT$32.37 Million ≈ $1.02 Million |
NT$2.50 Billion ≈ $78.79 Million |
-2.31pp |
| 2015-12-31 | 3.60% | NT$97.01 Million ≈ $3.06 Million |
NT$2.69 Billion ≈ $84.89 Million |
-2.58pp |
| 2014-12-31 | 6.18% | NT$163.51 Million ≈ $5.15 Million |
NT$2.64 Billion ≈ $83.33 Million |
-0.83pp |
| 2013-12-31 | 7.02% | NT$191.13 Million ≈ $6.02 Million |
NT$2.72 Billion ≈ $85.82 Million |
+5.26pp |
| 2012-12-31 | 1.76% | NT$48.38 Million ≈ $1.52 Million |
NT$2.75 Billion ≈ $86.58 Million |
-0.23pp |
| 2011-12-31 | 1.99% | NT$42.60 Million ≈ $1.34 Million |
NT$2.14 Billion ≈ $67.39 Million |
-0.01pp |
| 2010-12-31 | 2.00% | NT$38.99 Million ≈ $1.23 Million |
NT$1.95 Billion ≈ $61.45 Million |
-19.03pp |
| 2009-12-31 | 21.03% | NT$373.15 Million ≈ $11.76 Million |
NT$1.77 Billion ≈ $55.91 Million |
+19.69pp |
| 2008-12-31 | 1.34% | NT$19.88 Million ≈ $626.20K |
NT$1.49 Billion ≈ $46.80 Million |
-20.18pp |
| 2007-12-31 | 21.51% | NT$334.31 Million ≈ $10.53 Million |
NT$1.55 Billion ≈ $48.96 Million |
+17.55pp |
| 2005-12-31 | 3.97% | NT$44.45 Million ≈ $1.40 Million |
NT$1.12 Billion ≈ $35.30 Million |
-5.61pp |
| 2004-12-31 | 9.57% | NT$95.22 Million ≈ $3.00 Million |
NT$994.56 Million ≈ $31.33 Million |
-33.20pp |
| 2003-12-31 | 42.78% | NT$412.54 Million ≈ $13.00 Million |
NT$964.43 Million ≈ $30.38 Million |
+21.04pp |
| 2002-12-31 | 21.74% | NT$174.34 Million ≈ $5.49 Million |
NT$801.97 Million ≈ $25.27 Million |
-- |
About Apex Biotechnology Corp
Apex Biotechnology Corp. researches, develops, manufactures, and sells home care medical devices by using biosensor technology worldwide. The company offers blood glucose, uric acid, hemoglobin, cholesterol, lactate, HbA1C, and ketone monitoring systems, as well as coagulation and multifunctional self-testing. It also provides pesticide residue check systems; and care management and tele-health s… Read more